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a b s t r a c t
Transvenous lead extraction is becoming popular in Japan since the approval of laser extraction system
in 2010. The laser system seems to be the standard method used by most physicians, owing to its efﬁcacy
and ease of handling. The efﬁcacy and safety of this technology has been well proven in many studies
and the data suggest that it can be used for Japanese patients safely. However, lead extraction can cause
serious complications. Thus, it is important to learn the limitations as well as the basic techniques and
efﬁcacy of this procedure.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Laser-assisted lead extraction was approved in Japan in 2010.
The system itself has been in use in western countries for many
years and its effectiveness as well as safety has been proven in
many studies. Various methods are used for a transvenous lead
extraction. However, the laser-assisted system seems to be the
standard method used by most physicians, owing to its efﬁcacy
and ease of handling. Needless to say, any lead extraction method
has limitations and a risk of major adverse events (MAEs). It is
important, not only for the physicians but also for the medical staff
involved in this procedure, to understand the beneﬁts and limita-
tions of this system.
2. History
An excimer laser system for the extraction of permanent
pacemaker lead has been developed by Spectranetics Inc. (Color-
ado Springs, CO) and the ﬁrst extraction was performed by Dr.
Charles L. Byrd in 1994. In 1998 [1], Dr. Kennergren reported their
experiences to use an excimer laser. The initial model of laser
sheath (SLS I) was modiﬁed and a second-generation laser sheath
(SLS II) was launched in the market in 2002. The major improve-
ments included a more ﬂexible distal of the laser sheath up to
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10 cm and a slight bevel of the tip, as much as 151 (Fig. 1). The
efﬁcacy and safety of this laser sheath has been proven in many
articles throughout the literature. SLS II was approved in Japan
in 2010.
3. How it works
The laser sheath ﬁber-optically delivers the laser energy to the
distal end of the sheath, releasing the lead from the encapsulating
ﬁbrotic tissue. The sheath is constructed using 82 optical ﬁbers,
each with a core diameter of 100 μm, around an inner lumen. The
CVX 300 (Fig. 2, Spectranetics, Colorado Springs, CO) emits an
excimer laser beam utilizing xenon chloride, with an output of
308 nm, which falls in the ultraviolet region, not visible for
humans. This cool cutting laser has an absorption depth of
0.05 mm, the energy being absorbed by proteins and lipids. These
parameters are well suited for lead extraction, allowing cutting of
the tissue without damaging the veins or insulation of lead.
4. How to use
The SLS II laser sheath comes in three different sizes; 12 French
(F), 14 F, or 16 F (Fig. 2), according to the diameter of extracting
lead. Each sheath permits removal of lead with a maximum outer
diameter of 7.5 F, 9.5 F, and 11.5 F, correspondingly. The SLS II laser
sheath was positioned over the targeted lead and adhesions were
lysed using the laser when required (Fig. 3). The beveled edge of
the sheath was kept on the inside when approaching the brachio-
cephalic curve. The lead tip was freed by performing “counter
traction”, applying adequate traction to the lead while retaining
10 Cm SLS II
SLS
SLS II
Fig. 1. SLS II, the second-generation laser sheath. The tip of the sheath has a slight bevel of about 151 (left panel). The distal part, up to 10 cm, is more ﬂexible than the
original laser sheath (right panel).
12F14F16F
Fig. 2. (A) CVX 300 (Spectranetics, Colorado Springs, CO), the generator that emits an excimer laser utilizing xenon chloride with an output of 308 nm. (B) SLS II laser sheath
with a line up of three sizes. The sheath is constructed using 82 optical ﬁbers, each with a core diameter of 100 μm, around an inner lumen. (C) Mechanical outer sheath over
the inner laser sheath.
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the sheath in a position close to the atrial or ventricular endothe-
lium. To maintain a certain amount of tension in the lead, a
speciﬁc locking stylet is employed in most cases. When the laser
sheath cannot advance on its own, probably due to calciﬁed
adhesions, a mechanical outer sheath made of polytetraﬂuor-
oethylene (Fig. 2) can be applied. In addition, when the subclavian
approach does not work well, a femoral approach using a snare
catheter is helpful.
5. Efﬁcacy and safety
The PLEXES trial [2] was a randomized prospective clinical trial,
comparing the ﬁrst 12 F laser sheath to a non-laser cohort in 301
subjects, with 465 chronic pacemaker leads. Complete lead
removal rate was 94% in the laser group and 64% in the non-
laser group (p¼0.001). 88% of the time, the failed non-laser
extraction was completed using laser tools. The mean time to
achieve a successful lead extraction was also signiﬁcantly reduced
using laser tools, as compared to non-laser techniques (po0.04).
None of the non-laser techniques led to any potentially life-
threatening complications. However, such complications arose in
three of the laser patients, including one death (p¼NS).
Subsequently, in 2002, Byrd et al. [3] reported the laser lead
extraction of 2561 pacing and deﬁbrillator leads from 1684
patients at 89 sites in the United States. The procedural success
rate was 90%, with a major complication rate of 1.9% and an in-
hospital death rate of 0.8%.
Bordachar et al. [4] reported a prospective study comparing the
safety and effectiveness of laser sheaths to that of femoral snare
extractions. They showed that laser extraction was not only as safe
as the femoral approach but also reduces the procedure time and
the ﬂuoroscopic time.
The LExICon trial [5] was a retrospective multicenter study
using an SLS II laser sheath with a large number of patients (2405
leads from 1449 patients). In this study, leads were completely
removed 96.5% of the time, with a 97.7% clinical success rate. Thus,
clinical goals associated with the indication for lead removal were
achieved in most cases. The major adverse events seen in 20
patients, including 4 deaths (0.28%), were directly related to the
procedure (1.4%). This study showed an extremely high rate of
success and a low rate of adverse events. On the other hand, it
showed that failure to achieve clinical success was associated with
body mass index (BMI) o25 kg/m2 and low extraction volume
centers. Furthermore, major adverse effects were associated with
patients with a BMI o25 kg/m2.
6. Evidence from Japan
Okamura et al. [6] reported their ﬁrst experience of 40 cases
with laser sheath. The median duration of lead implantation was
87 months, which was comparable to the 82 months observed in
the LExICon trial [5]. The mean BMI value was 21.8 kg/m2 in their
patients. Based on the LExICon trial data, patients in their study,
including many low BMI patients and those having leads
implanted for many years, appeared to be at a higher risk for
procedure-related MAEs. However, the success rate of complete
removal was 97.1%, without any major complication.
Also, we can ﬁnd interesting case reports from Japanese centers
as well. Ohmori et al. [7] reported a case of thoracoscopy-guided
lead extraction with an excimer laser sheath and Okada et al. [8]
reported a case of transjugular extraction using a snare technique.
The data from Japan is limited but the number of cases of laser-
assisted lead extraction has been increasing dramatically year by
year. As of December 2014, it is performed in more than 30 centers
in Japan. It is thus important to accumulate data from experiences
in Japan and evaluate it properly. Accordingly, a case registration
system, led by Japanese Heart Rhythm Society is under
consideration.
7. Complications
MAEs can happen even if the extraction is performed without
any powered tool [9]. According to previous reports [3,10–15], the
Fig. 3. (Upper panel) Illustration of the working of the laser sheath. It is positioned over the targeted lead and adhesions are lysed using the laser when required. (Lower
panel) Fluoroscopic image when the laser sheath is positioned over the lead. White arrow shows the distal tip of the laser sheath. Note that the beveled edge of the sheath is
kept on the inside.
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MAE can happen in 1–3% of the cases. An especially serious
complication involves a tear of superior vena cava and a perfora-
tion of atrial or ventricular wall, which results in massive bleeding,
requiring emergent thoracotomy which can be fatal.
The deaths and cardiovascular injuries due to device-assisted
lead extraction have been reported by Hauser et al. [16]. They
searched the US Food and Drug Administration's (FDA) Manufac-
turers and User Deﬁned Experience (MAUDE) database from 1995
to 2008 and found 57 deaths and 48 serious cardiovascular
injuries associated with device-assisted lead extraction. The
majority of deaths and injuries involved ICD leads, and most were
caused by lacerations of the right atrium, superior vena cava, or
innominate vein. Overall, 62 patients underwent emergency
surgical repair of myocardial perforations and venous lacerations
and 35 (56%) of them survived.
Once the complication requiring thoracotomy occurs, the in-
hospital mortality is reported to be 36% [17]. To minimize this,
skilled standby cardiothoracic surgery is essential. Also, the
indications for transvenous lead extraction should be fully dis-
cussed and decided based on the Heart Rhythm Society (HRS)/
American Heart Association (AHA) 2009 consensus document [18].
8. Future device
Previous published results of laser lead extraction procedures
were obtained using laser sheaths delivering 40 pulses per second.
The 80-Hz GlideLight laser sheath, a new extraction tool delivering
double the number of pulses per second, has been approved in the
US in 2012. Hakmi et al. [19] have reported the ﬁrst experience of
using this new tool. A total of 76 leads were treated in 38 patients
using 80-Hz laser sheaths. The mean procedural time was
68.3 min and 94.8% of the leads were completely removed with
a clinical success rate of 97.4%. MAE of superior vena cava
perforation occurred in one case (2.6%), but no death was
recorded. The current 40-Hz laser sheath has enough efﬁcacy
and safety and hence, it is premature to mention the superiority of
this new 80-Hz laser sheath. However, the 80-Hz laser sheath may
reduce the need for mechanical force, thereby preventing intrao-
perative adverse events. Thus, we need to carefully observe future
results comparing these two laser sheaths.
9. Summary
Lead extraction using a laser sheath is an established method
with abundant positive evidence. Its efﬁcacy and safety have been
well proven, but complications can happen with a certain prob-
ability. It is thus important to accumulate our experience and
spread this therapy prudently for the patients who require lead
extraction.
Conﬂict of interest
H. Okamura plays the role of a trainer in the educational
program of laser-assisted lead extraction.
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